The goal of the University of Iowa/Mayo Clinic Lymphoma SPORE (UI/MC Lymphoma SPORE) CareerDevelopment Program (CDP) is to develop knowledgeable, well-trained scientists experienced inmultidisciplinary research for future studies in translational lymphoma research. The provision of ampleopportunities for training and career enhancement is a top priority of the University of Iowa and Mayo Clinicscientific communities. The extensive research and training base available at these two institutions providesstrong support for the UI/MC Lymphoma SPORE CDP. The primary objectives of the CDP are to: (1) trainyoung investigators (senior postdoctoral fellows and young faculty) in translational, multidisciplinary clinical orbasic lymphoma research; (2) redirect established investigators to further lymphoma research; and (3)collaborate with investigators from other institutions who are interested in pursuing a research career intranslational lymphoma research. During the initial funding period 6 young investigators received awards.Their work has led to the discovery of novel translocations, potential new methods of antigen presentation,and new treatments that are now being tested in clinical trials. During the next funding period, the UI/MCLymphoma SPORE will maintain: (1) a stringent candidate selection system; (2) comprehensive traineeguidance by a mentor and other investigators from both sites; (3) support through a scientific mentor group(the Individual Trainee Advisory Committee) comprised of investigators from both sites with expertise in eachtrainee's area of interest; (4) multi-disciplinary research courses and on-going training activities such as theMultidisciplinary Cancer Seminar Series and Lymphoma Group meetings at both sites; (5) encouragement ofcollaboration with Investigator Group meetings at both sites; (6) encouragement of collaboration withinvestigators at both Iowa and Mayo and (7) opportunities for research enhancement through theDevelopmental Research Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097274-06
Application #
7254605
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2007-08-17
Budget End
2008-06-30
Support Year
6
Fiscal Year
2007
Total Cost
$98,960
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Maurer, Matthew J; Ghesquières, Hervé; Link, Brian K et al. (2018) Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol 36:1603-1610
Huet, Sarah; Tesson, Bruno; Jais, Jean-Philippe et al. (2018) A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19:549-561
El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68
Tracy, Sean I; Habermann, Thomas M; Feldman, Andrew L et al. (2018) Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica 103:297-303
Mackrides, Nicholas; Chapman, Jennifer; Larson, Melissa C et al. (2018) Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. Am J Hematol :
McPhail, Ellen D; Maurer, Matthew J; Macon, William R et al. (2018) Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica 103:1899-1907
Hill, Brian T; Nastoupil, Loretta; Winter, Allison M et al. (2018) Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol :
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
J Pelletier, Daniel; O'Donnell, Michael; Stone, Mary Seabury et al. (2018) Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol 45:453-457
Thanarajasingam, Gita; Minasian, Lori M; Baron, Frederic et al. (2018) Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 5:e563-e598

Showing the most recent 10 out of 387 publications